PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Intraoperative Methadone in Spinal Fusion: Modest Early Benefit, Unresolved Safety

methadoneintravenous methadonemu-opioid agonistNMDA antagonistspinal fusionpostoperative painopioid-sparingmultimodal analgesiameta-analysisGRADEopioid stewardship Pain Management

Background Information

Methadone may reduce post-surgery pain in spinal fusion.

Methadone may provide extended pain relief and reduce opioid use in spinal fusion surgery. Methadone reduced pain scores at 24-72 hours and opioid consumption at 24 hours but showed uncertain clinical importance. The findings are limited by small trial sizes and low certainty in outcomes, suggesting methadone is not yet routine. Methadone offers a possible optional benefit in multimodal analgesia for spinal fusion.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Abu-Zaid A, Alhajri RB, Alsuhail GH, Alabkal FR, Boshehri FY, Alshammari MA, Alajmi NA, Albarrak BA, Alzufairi OF, Alenezi AF, Alhuwaimel YT, Alabdullah AK, Alharran AM

Citation: Abu-Zaid A, Alhajri RB, Alsuhail GH, et al. Intraoperative Intravenous Methadone Versus Non-Methadone Opioid Analgesia in Instrumented Spinal Fusion: A GRADE-Guided Systematic Review and Meta-Analysis. Journal of clinical medicine. 2026;15(21). doi:10.3390/jcm15218470

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.